Viking Therapeutics, Inc. (VKTX)
VKTXNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$28.91
+2.07 (+7.72%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $3.70bn
- P/E
- –
- EPS, last 4 quarters
- $-5.40
- Dividend yield
- –
- Day range
- –
- 52-week range
- $23.82 to $43.15
- Average volume
- 5.74m
- Previous close
- $26.84
Analysts
17 coveringBuy16 buy, 1 hold, 0 sell
Targets a year out average $93.29, +222.7% from here
Earnings
next estimate $-1.30Next report
Dec 2025
-55.1%
Mar 2026
-44.2%
Jun 2026
+9.1%
Sep 2026
-55.0%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$164.74m | -$164.13m | -$132.60m | -$187.11m |
| Net income | -$157.66m | -$158.32m | -$128.02m | -$183.19m |
News
8 latest- Novo Up 4% in a Month: How Should Investors Approach the Stock Now?Zacks · 16 hours ago
- Here's the 1 Stock I'd Most Want to Buy If the Market CrashesThe Motley Fool · 5 days ago
- Viking Therapeutics Trades 23% Below Its Own $35 Secondary Offering Price. Here's Why That Could Be a Gift for Patient Investors.The Motley Fool · 6 days ago
- How I'd Invest $10,000 Right NowThe Motley Fool · 6 days ago
- Novo Before Q3 Earnings: How Should Investors Play the Stock?Zacks · Nov 2, 2026
- UBS Just Initiated Coverage of Viking Therapeutics With a Buy Rating and a $94 Target. Here's the Bull Case.The Motley Fool · Nov 2, 2026
- VKTX: Is a 2029 Launch for Its Obesity Drug Within Reach?Zacks · Oct 30, 2026
- Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a BetZacks · Oct 30, 2026
The company
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company advancing a next-generation portfolio of therapies for obesity and metabolic disease. Guided by deep expertise in metabolic biology and rigorous science, Viking is developing innovative treatments to help people achieve meaningful, lasting health improvements by treating obesity first. The company's lead program, VK2735, is a dual glucagon-like peptide 1 ( GLP-1 ) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist in development in both subcutaneous and oral formulations for obesity. VK2735 is currently being evaluated in Phase 3 clinical studies for obesity, along with maintenance dosing strategies designed to support long-term weight management.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- vikingtherapeutics.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.